explore -WSS

explore

author：fashion 2025-09-06 03:39:46 - browse：92198

This image provided by Novo Nordisk in January 2023, shows packaging for the company's Wegovy drug. — Novo Nordisk via AP

PHILADELPHIA — Novo Nordisk’s obesity drug Wegovy notably cut the risk of heart attacks in a landmark cardiovascular trial that affirms the treatment offers health benefits beyond weight loss.

The company in August had announced that in this trial, called Select, Wegovy reduced the overall rate of major heart problems — heart attacks, stroke, or cardiovascular-related death — by 20%. That finding, which was the primary outcome the trial set out to study, was stronger than many were expecting and led Novo’s stock to surge.

But details of the study, including risk reductions for each specific heart complication, were not released until Saturday, when they were presented here — before a standing-room only crowd — as the first major session of the American Heart Association conference.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： AI can’t replace a physician’s gut feeling

hotspot

explore

WSS

How dance can help nurses traumatized by Covid

Cosmetics set for new safety regulation. Why the industry is on board

Listen: Wegovy in the brain & pivotal Alzheimer's data

AI can’t replace a physician’s gut feeling

In early work, researchers turn to CRISPR to treat Alzheimer's

How AI helped researchers track recovery from depression

focus

explore

Wikipedia

Moonlake's readout produced a cash windfall. Risks remain

A public scorecard can help hold safety

Guidelines to prevent youth baseball injuries need more muscle

Key House panel plots a new health care package

Jerome Adams on the need for new antivirals for Covid

What Congress can do to address the rural doctor shortage

Supreme Court strikes down use of affirmative action

In early work, researchers turn to CRISPR to treat Alzheimer's

Walensky prepares to leave CDC — and Congress — behind

As digital health tech proliferates, a new institute aims to cut through hype

explore

At Orexo, a ‘turning point’ for everything but digital health

Doctors find melanoma drugs effective against rare brain cancer

EHR maker NextGen Healthcare to pay $31M to resolve fraud claims

Readout LOUD podcast: possible new ALS drug, artificial wombs

Case for ALS therapy Nurown relies on ‘deficient’ data, FDA finds

Thermo Fisher plant for manufacturing gene therapies to expand

knowledge

hotspot

explore

explore